Acurx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET LOSS PER SHARE

NET LOSS PER SHARE	9 Months Ended
Sep. 30, 2023
NET LOSS PER SHARE
NET LOSS PER SHARE	NOTE 7 – NET LOSS PER SHARE Basic and diluted net loss per shares of common stock for the nine months ended September 30, 2023 and 2022 was determined by dividing net loss by the weighted average shares of common stock outstanding during the period. The Company’s potentially dilutive shares, consisting of 6,884,475 warrants and 2,985,000 stock options, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive.

NET LOSS PER SHARE

9 Months Ended

Sep. 30, 2023

NOTE 7 – NET LOSS PER SHARE

Basic and diluted net loss per shares of common stock for the nine months ended September 30, 2023 and 2022 was determined by dividing net loss by the weighted average shares of common stock outstanding during the period. The Company’s potentially dilutive shares, consisting of 6,884,475 warrants and 2,985,000 stock options, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive.